A5071983698- Multiple Sclerosis Research Studies
- Acute Lymphoblastic Leukemia research
- Autoimmune and Inflammatory Disorders Research
- Peripheral Neuropathies and Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Sphingolipid Metabolism and Signaling
- Rheumatoid Arthritis Research and Therapies
- Polyomavirus and related diseases
- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Prion Diseases and Protein Misfolding
- SARS-CoV-2 and COVID-19 Research
- Health, Environment, Cognitive Aging
- Radiomics and Machine Learning in Medical Imaging
- Infectious Diseases and Mycology
- Childhood Cancer Survivors' Quality of Life
- Mycobacterium research and diagnosis
- Medical Research and Treatments
- Long-Term Effects of COVID-19
- Neuroinflammation and Neurodegeneration Mechanisms
- Adolescent and Pediatric Healthcare
- Immunotherapy and Immune Responses
- Liver Diseases and Immunity
- Neutropenia and Cancer Infections
- Pneumonia and Respiratory Infections
Cleveland Clinic
2016-2025
Lou Ruvo Brain Institute
2016-2025
Case Western Reserve University
2016-2024
Cleveland Clinic Lerner College of Medicine
2024
Vall d'Hebron Hospital Universitari
2023
Johns Hopkins University
2023
Universitat Autònoma de Barcelona
2023
University of Manitoba
2019
Emory University
2018
Background: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is the first example of a learning health system in multiple sclerosis (MS). Methods: MS PATHS being conducted ten healthcare institutions three countries, each contributing standardized information acquired during routine care. Institutional participation required following: active patient census ≥500; at least one Siemens 3T magnetic resonance imaging scanner; willingness to standardize...
Research in multiple sclerosis (MS) has long been predicated on clinical groupings that do not reflect the underlying biologic heterogeneity apparent within patient populations. This review explicates various levels of explanation through which spectrum disease is described and investigated both above below threshold detection, as framed by topographical model MS, to help advance a cogent mechanistic framework.
Abstract Objective Evaluation of serum neurofilament light chain (sNfL), measured using high‐throughput assays on widely accessible platforms in large, real‐world MS populations, is a critical step for sNfL to be utilized clinical practice. Methods Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) network healthcare institutions the United States Europe collecting standardized clinical/imaging data biospecimens during routine clinic visits. was 6974 201 healthy...
Aims To describe the 12-month effectiveness, persistence, tolerability, and safety of ofatumumab (OMB), a highly effective disease-modifying therapy (DMT) for relapsing multiple sclerosis (MS), in real-world MS population.
Dimethyl fumarate and fingolimod are oral disease-modifying therapies approved to treat relapsing multiple sclerosis. Prior observational studies our previous 12-month investigation showed comparable clinical efficacy.
The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain.Post-SARS-CoV-2 blood samples across DMTs were tested for immunoglobulin G (IgG) response.Three hundred twenty-two people with MS included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) 40% anti-CD20 (32/80 patients); 41% sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% all other classes, including the no DMT...
Aim: To report experience with fingolimod in clinical practice. Design/Methods: Patients an academic medical center who were prescribed from October 2010 to August 2011 identified through the electronic record and followed for 12 months after initiation. Adverse effects (AEs), measures, MRI data, quality of life measures assessed. Results: Three hundred seventeen patients started fingolimod. Eleven treatment naïve (3.5%) 76 (24.0%) had remote disease modifying therapy (DMT) use prior One...
Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease-modifying therapies for relapsing multiple sclerosis (MS). Observational studies valuable when randomized clinical trials cannot be done due to ethical or practical reasons. Two-site allow investigators further ascertain external validity of previously examined treatment effect differences. Limited head-to-head 2-site exist comparing DMF FTY.Patients prescribed (n = 737) FTY 535) from 2 academic (MS) centers (Cleveland...
Aim: To assess time to improvement in Quality of Life Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Methods: Patients enrolled the MS PATHS network who initiated treatment either or ocrelizumab rated Neuro-QoL physical function, symptoms, emotional health, cognitive function and social ability. Results: Time clinically meaningful was significantly shorter (event ratio [95% CI]: 0.37 [0.24–0.57]; p < 0.001), sleep disturbance (0.45...
As the peak prevalence of multiple sclerosis (MS) shifts due to an aging patient population, understanding characteristics that define this older cohort improve overall management is critical. We sought determine clinical people with MS over age 60.
Many medical organizations have begun to confront the longstanding problem of inequalities in health care delivery and undeniable effect disparities on outcomes. The Consortium Multiple Sclerosis Centers (CMSC) recognizes that affect lives many people with multiple sclerosis (MS) acknowledges need address this as an organization. CMSC recently (1) appointed a task force, (2) conducted survey its membership, (3) commissioned review article call action, (4) formulated mission statement...
BackgroundDimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease modifying therapies (DMTs) for relapsing multiple sclerosis (MS). There currently no known head-to-head studies comparing DMF FTY over 36 months, which leaves their relative effectiveness unknown.ObjectiveTo assess real-world discontinuation, effectiveness, switching practices of months along with activity after DMT.MethodsPatients prescribed (n = 737) 535) from two academic MS centers were retrospectively...
Cost-effectiveness analyses tend not to take into account the availability of lower-priced generics following loss exclusivity (LOE) branded products. By considering these generics, which are typically adopted quickly, total costs likely be overestimated and may unreflective real-world payer conditions in United States.